Nonclinical evaluation of the potential for mast cell activation by an erythropoietin analog.


The erythropoietin analog peginesatide was withdrawn from marketing due to unexpected severe anaphylactic reactions associated with administration of the multi-use formulation. The adverse events occurred rapidly following the first ever administration of the drug with most affected patients becoming symptomatic in less than 30min. This is most consistent… (More)
DOI: 10.1016/j.taap.2015.06.009


Figures and Tables

Sorry, we couldn't extract any figures or tables for this paper.

Slides referencing similar topics